Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower

Immuneering Corporation (NASDAQ:IMRX) stock is trading lower on Thursday after the company shared updated data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) with a modified chemotherapy combination (gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer.Thirty-four (34) patients in the trial had over 13 months median follow-up time.Overall survival on the chemotherapy regimen after 12 months was 35%, compared to 64% in the atebimetinib combo trial.The survival was 83% in the atebime ...